RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

Trial Profile

RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms RECORA
  • Sponsors Bayer
  • Most Recent Events

    • 30 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Aug 2017.
    • 30 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Aug 2017.
    • 21 Jan 2017 Results (Data cut-off 11 July 2016) assessing efficacy (n=457) and safety (n=458) of regorafenib, presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top